Dynavax Technologies Corp (DVAX) shares surged over 5% in Friday's pre-market trading session, following the company's strong fourth-quarter earnings report and positive updates on its vaccine pipeline.
The biotech firm achieved record fourth-quarter and annual revenue for its hepatitis B vaccine, Heplisav-B, with net product sales expected to grow between $305 to $325 million in 2025. Dynavax has increased its market share to 44% in the US adult hepatitis B vaccine market, demonstrating robust commercial execution.
Furthermore, Dynavax made promising progress with its shingles vaccine candidate, Z1018, which showed comparable efficacy to the market leader Shingrix in phase 1 trials, but with improved tolerability. The company is also advancing its plague vaccine program in partnership with the US Department of Defense and expects to achieve significant milestones in its development pipeline this year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。